Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on…
U.S. CDC and FDA called for a pause in the J&J’s vaccine use following the emergence of a rare blood clotting disorder in six recipients.
BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) — VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical…
Preliminary Phase 1b findings in participants receiving the dual antigen hAd5 S + N vaccine generated Th1 dominant S and…
Opdivo is the first and only PD-1/L1 inhibitor to demonstrate superior first-line efficacy in upper GI cancers across histologies and…
-Preliminary data from 103 patients in the expansion portion of a Phase 1b clinical trial demonstrated the drug was well…
Potential to Treat Parkinson’s and Other Neurodegenerative Diseases VICTORIA, British Columbia–(BUSINESS WIRE)–$IPA #POLYTOPE–IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ:…
J&J has answered allegations about its batch of vaccines that could not be used after ingredient issues.
The U.S. Food and Drug Administration approved a new indication for Astellas Pharma’s Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
AstraZeneca’s AZD1222 got positive high-level results from the primary analysis of the Phase III trial which in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021.